PortfoliosLab logo
Tools
Performance Analysis
Risk Analysis
Optimization
Factor Model
See All Tools
Portfolio Analysis
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
Aclaris Therapeutics, Inc. (ACRS)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISINUS00461U1051
CUSIP00461U105
SectorHealthcare
IndustryBiotechnology

Highlights

Market Cap$84.81M
EPS-$1.09
PEG Ratio-0.13
Revenue (TTM)$31.12M
Gross Profit (TTM)-$60.02M
EBITDA (TTM)-$117.57M
Year Range$0.59 - $11.12
Target Price$1.84
Short %9.95%
Short Ratio7.98

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Aclaris Therapeutics, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Aclaris Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


-100.00%-50.00%0.00%50.00%100.00%150.00%December2024FebruaryMarchAprilMay
-89.23%
165.72%
ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

S&P 500

Returns By Period

Aclaris Therapeutics, Inc. had a return of 13.33% year-to-date (YTD) and -85.34% in the last 12 months.


PeriodReturnBenchmark
Year-To-Date13.33%11.18%
1 month-3.25%5.60%
6 months24.70%17.48%
1 year-85.34%26.33%
5 years (annualized)-26.76%13.16%
10 years (annualized)N/A10.99%

Monthly Returns

The table below presents the monthly returns of ACRS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
202410.48%2.59%4.20%-2.42%13.33%
20237.30%-26.27%-35.07%9.89%-6.07%24.19%-4.82%-24.21%-8.42%-27.30%-82.44%20.04%-93.33%
2022-24.90%36.45%15.70%-28.54%3.81%9.15%10.39%3.24%-1.07%-0.83%-2.50%3.48%8.32%
2021220.71%7.37%13.11%-5.36%-6.75%-21.04%-14.98%8.57%11.04%-3.61%-26.22%13.59%124.73%
2020-34.39%-8.06%-8.77%27.88%6.02%14.89%32.72%14.42%4.47%49.42%-13.02%93.71%242.33%
2019-5.68%-7.03%-7.56%5.18%-25.71%-53.21%-41.55%-21.09%6.93%62.04%-6.29%15.24%-74.42%
2018-10.30%-9.86%-12.14%1.31%1.80%10.51%-14.17%-7.12%-8.79%-18.11%-21.61%-20.71%-70.03%
2017-2.25%17.72%-4.51%-5.73%-15.40%14.05%6.19%-9.97%-0.46%-2.32%-5.95%4.01%-9.14%
2016-17.48%-17.50%3.33%-2.48%8.12%-7.56%6.66%2.34%27.03%-17.02%40.94%-9.38%0.74%
201530.95%62.75%14.39%143.80%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

The current rank of ACRS is 11, indicating that it is in the bottom 11% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.


The Risk-Adjusted Performance Rank of ACRS is 1111
ACRS (Aclaris Therapeutics, Inc.)
The Sharpe Ratio Rank of ACRS is 1010Sharpe Ratio Rank
The Sortino Ratio Rank of ACRS is 1818Sortino Ratio Rank
The Omega Ratio Rank of ACRS is 1313Omega Ratio Rank
The Calmar Ratio Rank of ACRS is 44Calmar Ratio Rank
The Martin Ratio Rank of ACRS is 1010Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for Aclaris Therapeutics, Inc. (ACRS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


ACRS
Sharpe ratio
The chart of Sharpe ratio for ACRS, currently valued at -0.76, compared to the broader market-2.00-1.000.001.002.003.004.00-0.76
Sortino ratio
The chart of Sortino ratio for ACRS, currently valued at -0.56, compared to the broader market-4.00-2.000.002.004.006.00-0.56
Omega ratio
The chart of Omega ratio for ACRS, currently valued at 0.88, compared to the broader market0.501.001.502.000.88
Calmar ratio
The chart of Calmar ratio for ACRS, currently valued at -0.87, compared to the broader market0.002.004.006.00-0.87
Martin ratio
The chart of Martin ratio for ACRS, currently valued at -1.26, compared to the broader market-10.000.0010.0020.0030.00-1.26
^GSPC
Sharpe ratio
The chart of Sharpe ratio for ^GSPC, currently valued at 2.38, compared to the broader market-2.00-1.000.001.002.003.004.002.38
Sortino ratio
The chart of Sortino ratio for ^GSPC, currently valued at 3.37, compared to the broader market-4.00-2.000.002.004.006.003.37
Omega ratio
The chart of Omega ratio for ^GSPC, currently valued at 1.42, compared to the broader market0.501.001.502.001.42
Calmar ratio
The chart of Calmar ratio for ^GSPC, currently valued at 1.94, compared to the broader market0.002.004.006.001.94
Martin ratio
The chart of Martin ratio for ^GSPC, currently valued at 9.12, compared to the broader market-10.000.0010.0020.0030.009.12

Sharpe Ratio

The current Aclaris Therapeutics, Inc. Sharpe ratio is -0.76. This value is calculated based on the past 12 months of trading data and takes into account price changes and dividends.

Use the chart below to compare the Sharpe ratio of Aclaris Therapeutics, Inc. with the selected benchmark, providing insights into the investment's historical performance in terms of risk-adjusted returns. Go to the Sharpe ratio tool for more fine-grained control over the calculation options.


Rolling 12-month Sharpe Ratio-1.000.001.002.003.00December2024FebruaryMarchAprilMay
-0.76
2.38
ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

Dividends

Dividend History


Aclaris Therapeutics, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%December2024FebruaryMarchAprilMay
-96.39%
-0.09%
ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the Aclaris Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aclaris Therapeutics, Inc. was 98.05%, occurring on Nov 13, 2023. The portfolio has not yet recovered.

The current Aclaris Therapeutics, Inc. drawdown is 96.39%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-98.05%Apr 18, 20171656Nov 13, 2023
-49.56%Dec 23, 201563Mar 24, 2016173Nov 29, 2016236
-19.68%Dec 19, 201634Feb 7, 201713Feb 27, 201747
-13.11%Nov 24, 20157Dec 3, 20159Dec 16, 201516
-12.04%Mar 7, 201711Mar 21, 201718Apr 17, 201729

Volatility

Volatility Chart

The current Aclaris Therapeutics, Inc. volatility is 14.59%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


0.00%50.00%100.00%150.00%200.00%December2024FebruaryMarchAprilMay
14.59%
3.36%
ACRS (Aclaris Therapeutics, Inc.)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Aclaris Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Income Statement


Income Statement
Balance Sheet
Cash Flow
Annual
Quarterly

TTM
Revenue

Total Revenue

0.00

Cost Of Revenue

0.00

Gross Profit

0.00
Operating Expenses

Selling, General & Admin Expenses

0.00

R&D Expenses

0.00

Total Operating Expenses

0.00
Income

Income Before Tax

0.00

Operating Income

0.00

EBIT

0.00

Earnings From Continuing Operations

0.00

Net Income

0.00

Income Tax Expense

0.00

Interest Expense

0.00

Other Non-Operating Income (Expenses)

0.00

Extraordinary Items

0.00

Discontinued Operations

0.00

Effect Of Accounting Charges

0.00

Non Recurring

0.00

Minority Interest

0.00

Other Items

0.00
Values in undefined except per share items